We are live on ! Find out more
MRTX

Mirati Therapeutics, Inc. Common Stock
MRTX

Delisted

MRTX was delisted on the 22nd of January, 2024.

Back to rankings

177 hedge funds and large institutions have $3.36B invested in Mirati Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 68 increasing their positions, 57 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more call options, than puts

Call options by funds: $221M | Put options by funds: $159M

21% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 24

19% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 57

3% more funds holding

Funds holding: 172 → 177 (+5)

25% less capital invested

Capital invested by funds: $4.48B → $3.36B (-$1.12B)

54% less funds holding in top 10

Funds holding in top 10: 13 → 6 (-7)

Holders
177
Holders Change
+5
Holders Change %
+2.91%
% of All Funds
3.88%
Holding in Top 10
6
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-53.85%
% of All Funds
0.13%
New
29
Increased
68
Reduced
57
Closed
24
Calls
$221M
Puts
$159M
Net Calls
+$61.5M
Net Calls Change
-$44.3M

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$50.2M
2
CAM
Cormorant Asset Management
Massachusetts
+$46.9M
3
PHS
PFM Health Sciences
California
+$40.5M
4
PA
Perceptive Advisors
New York
+$38.9M
5
RI
RTW Investments
New York
+$31.7M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$113M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$69.4M
3
FCM
Farallon Capital Management
California
-$65.2M
4
EC
EcoR1 Capital
California
-$51.9M
5
VC
Vivo Capital
California
-$24M
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
126
BlueCrest Capital Management
Jersey
$582K +$702K +7,475 New
CEP
127
Chicago Equity Partners
Illinois
$539K -$721K -7,680 -53%
AR
128
Advisory Research
Illinois
$479K -$725K -7,724 -56%
XK
129
Xact Kapitalforvaltning
Sweden
$467K +$131K +1,400 +30%
PIM
130
Partner Investment Management
California
$418K +$504K +5,370 New
AL
131
AJO LP
Pennsylvania
$391K +$472K +5,029 New
BNP Paribas Financial Markets
132
BNP Paribas Financial Markets
France
$384K +$166K +1,772 +56%
DC
133
Diametric Capital
Massachusetts
$383K +$461K +4,916 New
QSS
134
Quantitative Systematic Strategies
Florida
$365K +$192K +2,045 +78%
JGC
135
J. Goldman & Co
New York
$346K -$1.71M -18,209 -80%
AB
136
Amalgamated Bank
New York
$345K -$5.63K -60 -1%
Mirae Asset Global Investments
137
Mirae Asset Global Investments
South Korea
$338K +$407K +4,336 New
DY
138
Dowling & Yahnke
California
$335K -$93.9K -1,000 -19%
Simplex Trading
139
Simplex Trading
Illinois
$328K -$1.86M -19,860 -82%
Public Employees Retirement Association of Colorado
140
Public Employees Retirement Association of Colorado
Colorado
$323K – – –
ARTA
141
A.R.T. Advisors
New York
$315K -$160K -1,700 -30%
VF
142
Virtu Financial
New York
$294K +$354K +3,776 New
Royal Bank of Canada
143
Royal Bank of Canada
Ontario, Canada
$289K +$8.45K +90 +2%
Creative Planning
144
Creative Planning
Kansas
$245K – – –
PCM
145
Prelude Capital Management
New York
$233K +$281K +2,993 New
CG
146
Cutler Group
California
$225K -$418K -4,450 -61%
VEA
147
Virtus ETF Advisers
New York
$210K -$14K -149 -5%
AIP
148
Ameritas Investment Partners
Nebraska
$176K +$12.4K +132 +6%
TAM
149
Tiverton Asset Management
Delaware
$120K – – –
SO
150
STRS Ohio
Ohio
$116K – – –
4 5
6
7 8

MRTX Hedge Fund Activity: Q3 2019 in Review

177 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q3 2019, worth a combined $3.36B — down 25% from $4.48B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new MRTX positions and 24 closed out — a net gain of 5 holders — while 68 added to existing stakes and 57 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $50.2M. The largest seller was Baker Bros. Advisors, cutting an estimated $113M.

  • 177 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q3 2019, up from 172 in Q2 2019.
  • Funds reported $3.36B of Mirati Therapeutics, Inc. Common Stock stock for Q3 2019, down 25% quarter-over-quarter.
  • 29 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q3 2019 and 24 closed out, a net change of +5 holders.
  • The largest Mirati Therapeutics, Inc. Common Stock buyer in Q3 2019 was OrbiMed, an estimated $50.2M added.
  • The largest Mirati Therapeutics, Inc. Common Stock seller in Q3 2019 was Baker Bros. Advisors, an estimated $113M sold.

Based on aggregated 13F filings for Q3 2019.